Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : F. Hoffmann-La Roche Ltd
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
Estudio fase II, aleatorizado, doble ciego, multicéntrico de búsqueda de dosis que evalúa la eficacia y seguridad del profármaco inhibidor de la polimerasa VHC (RO4588161) cuando se asocia con Pegasys® y Copegus® comparado con la asociación actualmente aprobada de Pegasys® y Copegus® en el tratamiento de pacientes sin tratamiento previo con infección por el virus de la hepatitis C crónica genotipo 1 A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) when given in combination with Pegasys® and Copegus® versus the currently approved combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 Virus infection
Determinar la asociación de tratamiento óptima basándose en la eficacia y seguridad del profármaco inhibidor de la polimerasa del VHC (RO4588161) en asociación con Pegasys y Copegus comparado con la a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome
- To evaluate the efficacy of single-agent vismodegib in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) as measured by overall response rate (ORR).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab plus Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma
• To determine the recommended Phase II dose (RP2D) for lenalidomide (Len) when given in combination with fixed doses of obinutuzumab (G) and atezolizumab (Atezo) • To evaluate the safety and tolerab...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
Randomized, two arm, controlled study to compare the efficacy of oral ibandronate treatment versus intravenous zoledronate in patients with symptomatic Multiple Myeloma
• To assess the efficacy of oral ibandronic acid 50 mg compared to intravenous zoledronate based on proportion of patients with Skeletal Related Event’s (SREs, defined as fractures, the need for radio...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A two-part, randomized Phase II, double-blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum resistant epithelial ovarian cancer and low HER3 mRNA expression STUDIO IN DUE PARTI, RANDOMIZZATO, DI FASE II, IN DOPPIO CIECO,MULTICENTRICO PER LA VALUTAZIONE DELL'EFFICACIA E DELLA SICUREZZA DI PERTUZUMAB IN ASSOCIAZIONE CON CHEMIOTERAPIA STANDARD RISPETTO A PLACEBO IN ASSOCIAZIONE CON CHEMIOTERAPIA STANDARD IN DONNE AFFETTE DA CARCINOMA OVARICO EPITELIALE RICORRENTE, RESISTENTE AL PLATINO E CARATTERIZZATO DA BASSA ESPRESSIONE DELL'mRNA DI HER3
Part 1: Safety Run-in Phase The primary objective for Part 1 of this study is as follows: -To determine the safety and tolerability of pertuzumab in combination with either topotecan or paclitaxel. ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
Assessment of the acceptability of up to 200 Days of Valganciclovir Oral Solution or Tablets in children who have received a Kidney Transplant
• The primary objective of this study is to describe the tolerability profile of up to 200 days prophylaxis of valganciclovir oral solution and tablets in pediatric kidney transplant recipients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
An open label study to determine the effect of R1507 (RO4858696) plus Tarceva (erlotinib) on progression-free survival in patients with stage IIIB/IV non-small cell lung cancer with progressive disease after clinical benefit to second or third line erlotinib monotherapy
To define PFS rate at 12 weeks in patients with advanced stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) who have progressive disease after clinical benefit, defined as response or stable disease at ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
The primary objective of the Phase I portion of the study is: • To estimate the maximum tolerated dosing schedule for venetoclax given in combination with R-CHOP or G-CHOP to patients with B-cell NHL...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program
To assess the safety profile of bevacizumab when combined with fluoropyrimidine-based chemotherapy regimens as first line treatment of metastatic cancer of the colon or rectum.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell carcinoma
To assess the PFS of bevacizumab (10mg/kg i.v. every two weeks) in combination with a low dose of interferon alpha-2a (IFN) (3 MIU s.c. three times per week [t.i.w.]) administered until disease progre...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
12
13
14
15
16
17
18
19
20
21
Suivant